Shenzhen Kisshealth Biotechnology Co., Ltd

Keep It Simply and Smartly for Healthcare!

Manufacturer from China
Active Member
4 Years
Home / Products / Antigen Detection Kit /

SARS-CoV-2 Antigen Rapid Detection Kit Immunofluorescence 5 Tests

Contact Now
Shenzhen Kisshealth Biotechnology Co., Ltd
City:shenzhen
Country/Region:china
Contact Person:MsMeiko Wu
Contact Now

SARS-CoV-2 Antigen Rapid Detection Kit Immunofluorescence 5 Tests

Ask Latest Price
Video Channel
Brand Name :KISSH
Model Number :K903-1
Certification :CE
Place of Origin :CHINA
MOQ :1000 tests
Price :Negotiable
Payment Terms :T/T
Supply Ability :1,000,000 tests per day
Delivery Time :Within 7 days
Packaging Details :1 Test/Kit, 5 Tests/Kit, 10 Tests/Kit, 20 Tests/Kit
Product namee :SARS-CoV-2 Antigen Detection Kit(Immunofluorescence)
Usage :Qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal (NP), nasal swab and saliva specimens
Sample Type :Nasopharyngeal (NP) and Nasal swab,Saliva,Oropharyngeal (OP) swab
Pattern :KISSH
Methodology :Immunofluorescence
Function :Delta Variant Detection
more
Contact Now

Add to Cart

Find Similar Videos
View Product Description

SARS-CoV-2 Antigen Detection Kit(Immunofluorescence)

Product Information

Product name SARS-CoV-2 Antigen Detection Kit(Immunofluorescence)
Main Composition Test Cassette individually foil pouched with a desiccant, Sample Tube, with cap and antigen extraction buffer,Sampling swab, Instruction for use
Package 1 Test/Kit
Keep temperature 2-30℃
Shelf-life 12 months
Place of Origin Shenzhen China

Basis Information

The product is intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal (NP) and nasal swab, saliva specimens and superficial nasal swab directly from individuals who are suspected of COVID- 19 by their healthcare provider.

Results are to identify SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.

Negative results should be treated as presumptive and confirmed with a molecular assay, if necessary for patient management. Negative results do not rule out COVID- 19 and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID- 19.The Antigen test kit is intended for use by trained clinical laboratory personnel and individuals trained in point of care settings.

Inquiry Cart 0